Stock data
BioCryst Pharmaceuticals, Inc. (BCRX)
BioCryst Pharmaceuticals, Inc. (BCRX) reported net income of US$263.86M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | US$340.99M | US$263.86M | — |
| 2024 | — | — | -US$2.54M | -US$88.88M | — |
| 2023 | — | — | -US$103.71M | -US$226.54M | — |
| 2022 | — | — | -US$148.44M | -US$247.12M | — |
| 2021 | — | — | -US$177.72M | -US$184.06M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | US$78.39M | — |
| 2026-03-31 | — | -US$721.81M | — |
| 2025-12-31 | — | US$245.84M | — |
| 2025-09-30 | — | US$12.90M | — |
| 2025-06-30 | — | US$5.08M | — |
| 2025-03-31 | — | US$0.03M | — |
| 2024-12-31 | — | -US$26.80M | — |
| 2024-09-30 | — | -US$14.03M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.